ArticleMedical oncology (Northwood, London, England)2013
Expression of synuclein gamma indicates poor prognosis of triple-negative breast cancer.
Article in Medical oncology (Northwood, London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 18 citations in OpenAlex.
- α-synuclein expression in glioblastoma restores tumor suppressor function and rescues temozolomide drug resistance.Cell death & disease · 2025Article
- Cancer in pathologically confirmed multiple system atrophy.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2023Article
- Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study.Cancer · 2017Article
- Alpha-synuclein contributes to malignant progression of human meningioma via the Akt/mTOR pathway.Cancer cell international · 2016Article
- The Breast Cancer Susceptibility Gene Product (γ-Synuclein) Alters Cell Behavior through its [corrected] Interaction with Phospholipase Cβ.Cellular signalling · 2016Article
- Identification of γ-synuclein as a stage-specific marker in bladder cancer by immunohistochemistry.Medical science monitor : international medical journal of experimental and clinical research · 2014Article
- Synuclein-gamma predicts poor clinical outcome in esophageal cancer patients.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markers.Journal of thoracic disease · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synuclein gamma (SNCG), previously identified as breast cancer-specific gene 1, is highly expressed in malignant cells but not in normal epithelium. Studies have demonstrated that the expression of SNCG is an independent predictive marker for recurrence and metastasis in breast cancer. Triple-negative breast cancer (TNBC) is characterized by a lack of expression of both the estrogen receptor and progesterone receptor proteins as well as HER-2 and is often associated with particularly poor outcomes, early development of chemotherapy resistance, and ineffectiveness of targeted therapy. This study aimed to reveal whether SNCG-positive TNBC is more likely than SNCG-negative TNBC to have a more aggressive phenotype. One hundred and two TNBC patients were divided into two groups according to the SNCG protein expression. Clinical and biological features of SNCG-positive tumors were compared with SNCG-negative tumors. Association between survival and SNCG expression was analyzed by the Kaplan-Meier method. Hazard ratios and 95 % confidence intervals (CIs) were calculated using Cox regression. And 34.3 % TNBCs showed moderate to strong positive SNCG expression. Patients whose tumors expressed SNCG had significantly shorter disease-free survival (P = 0.013) and a higher probability of death (P = 0.002) when compared with those whose tumors did not express SNCG. The hazard ratio of metastasis or recurrence based on SNCG expression status was 2.800 (95 % CI 1.193-6.574; P = 0. 018). There was no significant correlation between SNCG expression and age, lymph node involvement, and tumor stage histological type, except tumor size which was significantly associated with SNCG expression (P = 0.032, R = 0.212). This study suggests that SNCG expression indicates [Symbol: see text]correlates with?[Symbol: see text] a much poorer prognosis of TNBC. SNCG is expected to be a useful marker for TNBC progression and a potential target for TNBC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.